



SUVEN Life Sciences

Communication to investors **June 2018**

14-Aug-18

2018-19 Q1 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 1 – June 2018



	Q1-FY19 to Q4-FY18	Q1-FY19 to Q1-FY18
Growth in Revenue	-10.39%	36.24%
Growth in PAT	-37.77%	31.23%
Growth in EBIDTA	-33.95%	30.35%
Growth Pre-R&D EBIDTA	-29.85%	23.05%
Increase in R&D costs	-5.48%	-0.14%




MAJOR PROFITABILITY RATIOS

	30 Jun 2018	31 Mar 2018	30 Jun 2017
PAT to Income	19.41%	27.95%	20.15%
EBIDTA to Income	33.21%	45.06%	34.72%
Cash Flow to Income	22.16%	30.35%	23.69%
Pre-R&D EBITDA to Income	41.22%	52.65%	45.64%
R&D to Income	8.00%	7.59%	10.92%



INCOME COMPARISON




14-Aug-18

2018-19 Q1 results



PROFIT COMPARISON




14-Aug-18

2018-19 Q1 results




EBIDTA COMPARISON



14-Aug-18

2018-19 Q1 results

R & D – EXPENDITURE




14-Aug-18

2018-19 Q1 results



PRE-R&D EBIDTA




14-Aug-18

2018-19 Q1 results



PRE-R&D CASHFLOW



14-Aug-18

2018-19 Q1 results



Financial Snapshot

All figures are in INR Million, other than ratios and EPS

	Q1 FY19	Q4 FY18	QoQ growth	Q1 FY18	YoY growth
Income	1,997.90	2,229.49	-10.39%	1,466.42	36.24%
Pre-R&D EBITDA	823.47	1,173.83	-29.85%	669.22	23.05%
Pre-R&D EBITDA Margin	41.22%	52.65%	-	45.64%	-
EBITDA	663.59	1,004.68	-33.95%	509.10	30.35%
EBITDA Margin	33.21%	45.06%	-	34.72%	-
EBIT	607.81	949.03	-35.95%	456.94	33.02%
EBIT Margin	30.42%	42.57%	-	31.16%	-
Financing costs	10.68	12.54	-	12.70	-
Taxes	209.41	313.42	-	148.77	-
Taxes to Profit	35.07%	33.47%	-	33.49%	-
Net Profit after tax	387.73	623.07	-37.77%	295.46	31.23%
NP Margin	19.41%	27.95%	-	20.15%	-
EPS (basic & diluted not annualized)	3.05	4.90	-	2.32	-
Paid up share capital One Rupee Share)	127.28	127.28	-	127.28	-
Depreciation	55.08	53.61	-	51.92	-
R&D expenses	159.89	169.15	-5.48%	160.12	-0.14%

14-Aug-18

2018-19 Q1 results



News Updates

- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in USA, so far enrolled 494 patients against target of 537 patients in the study.
- During the period Suven secures 15 product patents covering countries - Australia, China, India, Israel, Mexico, New Zealand, Norway, Singapore, South Korea and USA
- Suven Life Sciences participated in Sleep 2018 conference held in Baltimore in June 2018
- Suven Life Sciences participated and presented in Jefferies Global Healthcare Conference held in New York in June 2018
- Suven Life Sciences exhibited and presented in AAIC 2018, held in Chicago in July 2018